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Improving mid-term and long-term outcomes after
solid organ transplantation is imperative, and
requires both state-of-the-art transplant surgery
and optimization of routine, evidence-based after-
care. This randomized, controlled trial assessed the
effectiveness of standard aftercare versus telemedi-
cally supported case management, an innovative
aftercare model, in 46 living-donor renal transplant
recipients during the first posttransplant year. The
model includes three components: (i) chronic care
case management initiated after discharge, (ii) case
management initiated in emerging acute care situa-
tions, and (iii) a telemedically equipped team com-
prising a transplant nurse case manager and two
senior transplant physicians (nephrologist, sur-
geon). Analyses revealed a reduction of unplanned
inpatient acute care, with considerable cost reduc-
tions, in the intervention group. The prevalence of
nonadherence over the 1-year study period was
17.4% in the intervention group versus 56.5% in
the standard aftercare group (p = 0.013). Only the
intervention group achieved their pre-agreed levels
of adherence, disease-specific quality of life, and
return to employment. This comparative effective-
ness study provides the basis for multicenter study
testing of telemedically supported case
management with the aim of optimizing posttrans-
plant aftercare. The trial was registered with the
German Clinical Trials Register (www.DRKS.de),
DKRS00007634.
Abbreviations: ALL, Fragebogen Alltagsleben (Ques-
tionnaire of Daily Living); ATS, ANOVA-type statistic;
BAASIS, Basel Assessment Adherence to Immuno-
suppression Scale; BSI-18, Brief Symptom Inventory
18; CAS, composite adherence score; CKD-EPI, Chronic
Kidney Disease Epidemiology Collaboration; DGCC,
German Association for Care and Case Management;
DRG, diagnosis-related group; ESRD-SCLTM, End-Stage
Renal Disease Symptom Checklist-Transplantation
Module; IQR, interquartile range; RTR, renal transplant
recipient; SOCG, standard of care group; STP, senior
transplant physician; TNCM, transplant nurse case
manager; TSCMG, telemedically supported case man-
agement group; T, time point; TX, Transplantation;
UMC, University Medical Center
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Introduction
The organ shortage crisis in Germany has led to an aver-
age waiting time for deceased donor kidney transplants of
approximately 10 years. This situation demands alterna-
tive solutions. Living-donor renal transplantation has
become an important focus at the University Medical Cen-
ter (UMC) Freiburg. Attaining the best possible mid-term
and long-term outcomes for renal transplant recipients
(RTR), however, requires both state-of-the-art surgery
and optimization of routine evidence-based aftercare—a
complex challenge.
Promoting adherence within a tailored approach is a key
requirement. Following the development of various
chronic disease self-management (1) and case manage-
ment (2) approaches for chronic conditions in general,
De Geest et al. (3) went one step further and advanced
the concept of chronic illness management for trans-
plant recipients. To date, only a small number of
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structured programs for RTR have been described,
mainly focused on self-management (4–7). Case man-
agement solves complex, intrapersonal, interpersonal,
and environmental concerns. According to criteria set out
by Klie (8), case management is advisable in the first year
posttransplant, involving various sectors and healthcare
providers, and demanding high standards of care continu-
ity and patient participation. Advanced levels of patient
self-responsibility, self-care, and self-management are
required, but it is recognized that this may not be achiev-
able for RTRs. Dew et al. detected a high prevalence of
nonadherence (35.6%) in this setting (9), and De Geest
et al. (10) observed that 16–36% of graft losses are asso-
ciated with nonadherence, a finding confirmed elsewhere
(11–14).
The benefit of telemedicine for delivering effective care
coordination in chronic disease conditions has been
confirmed in settings such as cardiac insufficiency.
Video technology is efficient. Evidence for remote tele-
monitoring with no human involvement is scarce and,
instead, the combination of both remote and personal
contact is likely to ensure earlier treatment in response
to deterioration (15–18). Consequently, the UMC Frei-
burg designed a telemedically supported aftercare pro-
ject in cooperation with the UMC Strasbourg, France,
which was funded by the European Union within the
framework of the INTERREG IV Oberrhein program
(19). Technical equipment and services were shared.
However, the nature of aftercare necessarily differed
between the French liver and German kidney transplant
recipients. Due to limited resources, the Freiburg pro-
ject was offered only to living-donor RTR, justified
because of the higher need to avoid nonadherence
(12,14,20). Complete adherence to the immunosuppres-
sive regimen and self-care is crucial. To support this,
our priority was to achieve daily patient participation in
remote telemonitoring, rather than patient “control.”
Therefore, we did not plan electronic monitoring of
immunosuppressant intake via telemedical equipment.
Sch€afer-Keller et al. (21) have proposed an alternative
measurement method using a composite adherence
score (CAS) that provides acceptable sensitivity (72%)
and accuracy (42%) when compared to electronic
monitoring.
Video consultations may not only help to detect deterio-
ration promptly, but also enable patients to explain and
discuss barriers to full adherence. Telemedically sup-
ported case management could transform posttransplant
aftercare if it provides instant delivery of tailored ser-
vices, even for more complex clinical challenges. This
could potentially lower the risk for acute complications or
graft rejection and the associated need for medical ser-
vice utilization. We hypothesized that this approach
would support stable adherence with improved quality of
life and quasi-normal living, promoting better long-term
outcomes.
Materials and Methods
Study design
This was a prospective, open-label, randomized comparative effective-
ness study that used a repeated-measures design (19,22). The Ethics
Committee of the Albert-Ludwigs-University Freiburg, Germany (608/14)
approved the study protocol.
All adult living donor RTRs at the UMC Freiburg were eligible. After writ-
ten, informed consent to a concealed allocation to either standard or
interventional aftercare, literate German speakers with the ability to take
medication independently were included. Randomization was then per-
formed using a computer-generated randomization schedule provided by
the Institute of Medical Biometry and Medical Informatics, Freiburg.
General healthcare followed evidence-based, good clinical practice stan-
dards as determined by the German Agency for Quality Assurance in
Medicine. German health insurance is bound by law to guarantee these
standards for all citizens equally. The treatment and drug regimens of
each participant were covered by insurance.
Standard of care group (SOCG)
The posttransplant immunosuppressive regimen comprised tacrolimus,
mycophenolic acid, and prednisone (23). Prior to discharge, all RTR
received a booklet for recording drug regimen, vital signs, and fluid bal-
ance, as well as an educational booklet (24). Additionally, a transplant
nurse provided counseling, which included standardized self-manage-
ment information about disease prevention, immunosuppression adher-
ence, and self-monitoring. Thereafter, regular checkups with a resident
nephrologist were combined with a best clinical practice checkup pro-
gram at the UMC Freiburg. The physicians determined the time inter-
vals between checkups according to risk stratification, and offered
further consultations whenever needed. The UMC Freiburg reports pro-
vided updated diagnoses, laboratory values, and medical treatment regi-
men. Additional checkups with other specialists were advocated where
appropriate.
Telemedically supported case management group (TSCMG)
This group received the same standard of care and telemedically sup-
ported case management. Key features are summarized in Table 1. Our
aim was to apply patient-centeredness and adherence to best clinical
practice. Therefore, we strived for quality, quantity, and promptness in
the availability of significant information via a tailored telemedically sup-
ported case management model. The model includes three basic compo-
nents: (i) a chronic case management process for the first year
posttransplant; (ii) a case management process applicable for acute care
situations; and (iii) a telemedically equipped team. Members comprised a
transplant nurse case manager (TNCM) and two senior transplant physi-
cians (STP: surgeon and nephrologist). All team members were employed
by the UMC Freiburg. Their combined activities constituted each com-
plete case management process, including initiation, assessment, plan-
ning, linking, monitoring, and evaluation.
Preconditions: A key factor was the consensus of the team and the
medical network on patient-centered care. Figure 1 shows the
collaboration structures and information pathways.
Telemedical aspects: Prior to discharge, the TNCM trained each RTR
in the operation of an interactive terminal. It enabled remote
telemonitoring and prompt real-time video consultations. For
telemonitoring, the RTR answered standardized multiple-choice
questionnaires via the terminal once a day. This included semi-open
questions about fluid balance and vital signs, as well as closed-ended
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questions about immunosuppression intake and disease-specific
symptoms. The daily entry of self-measured data for telemonitoring also
helped the patients form good habits.
For security, the data were transferred through a safe web-based con-
nection. Therefore, the patient terminal was not a mobile device. Supple-
mentary briefings were provided via calls, voice mailbox, Short Messages
Services, and emails to the TNCM’s mobile telephone, ensuring prompt
responses. The TNCM was also equipped with a disconnected security
token that allowed 24-h online access to all significant medical data at
the UMC Freiburg. Device codes, user codes, passwords, and firewalls
ensured overall protection.
Case management aspects: We followed the recommendations
from the German Association for Care and Case Management (DGCC)
(25), supplemented by provision of direct medical services tailored for
RTR.
The chronic care case management process started for each RTR at hos-
pital discharge. After assessment, the TNCM provided planning, linking,
Table 1: Core features and cost estimation of telemedically supported case management
Preconditions: Consensus of personnel and medical network on patient-centered care
Overall essence, goals
and strategies:
A chronic illness approach for renal transplant recipients with focus on adherence to jointly agreed goals and
related medical instructions via instant expert services for individualized chronic care management and
also appropriate management during acute phases in the first year posttransplant
Core activities and their
providers:
Telemedically supported case management services (see below) delivered by an interdisciplinary case
management team of transplant center experts
Staffing: personnel
participants
 Case management team members:
o2 senior transplant physicians (STP)
o1 transplant nurse case manager (TNCM)
 Renal transplant recipients
Cost estimation for 23 patients:
50% TNCM position €28 500
Internal server provision €1024
Equipped team workplace €500
Extra patient-variable costs:
Touchscreen terminals with
software licenses 9 23 €20 700
Extra infrastructure costs: €12 681
€63 405: 23 = €2757 per patient
Materials: (recipients) 1 internal server provision (TNCM) including 1
security token (TNCM)1 laptop & 1 mobile phone (TNCM)
Touchscreen terminals (STP, participants) including software licenses
Application of telemedical services: Timing Provider Delivery Intensity
(availability) (8 am–2 pm on weekdays & for urgency 8 am–9 pm daily)
 Remote telemonitoring
 Real-time video consultations with access
to significant medical data at
the University Medical Center for:
o case management services
o medical consultation/instructions
o extra self-care-related education
o extra self-management support
o coaching in health-specific issues
Every day TNCM Person-independent Once daily
(See below) TNCM Person-dependent Tailored to needs
On request STP Person-dependent Tailored to needs
On request TNCM Person-dependent Tailored to needs
On request TNCM Person-dependent Tailored to needs
On request TNCM Person-dependent Tailored to needs
Applied methods in telemedical
education, support & coaching:
Advocacy, individualization, consciousness raising, patient-driven learning,
proactive information, goal setting, self-monitoring, feedback, planning coping
responses, discussion, personalized-risk and scenario-based risk information
Application of case
For the chronic care situation For a new acute care situation
management services: Timing Provider Delivery Timing Provider Delivery
(availability): (regularly 8 am–2 pm on weekdays) (On standby 8 am–9 pm daily)
Process initiation TX + 1 week TNCM Face-to-face Urgency TNCM Mobile phone
Assessment/
reassessments
TX + 1 week/
Tailored to needs
TNCM Face-to-face/
telemedically
Very timely
after the
process
initiation
TNCM/
TNCM
Telemedically/
Mobile phone
Service planning/
additional planning
TX + 1 week/
Tailored to needs
STP &
TNCM
Face-to-face/
telemedically
STP/
TNCM
Mobile phone/
mobile phone
Linking to providers
and care coordination
Early after planning,
tailored to needs
STP &
TNCM
Mobile phone,
written report
STP Mobile phone
Monitoring Weekly to biweekly
written case notes
TNCM Telemedically,
mobile phone
Every day STP or
TNCM
Face-to-face,
mobile phone
Final evaluation TX + 1 year TNCM Face-to-face Patient’s
recovery
STP or
TNCM
Face-to-face,
telemedically
STP, senior transplant physician; TNCM, transplant nurse case manager; TX, transplantation.
1596 American Journal of Transplantation 2017; 17: 1594–1605
Schmid et al
and monitoring for the achievement of jointly agreed medical goals,
underpinned by self-management and self-care-related actions. The RTR
had continuous access to an expert to discuss how to deal with specific
challenges, and how to set informed health-protection priorities in daily
living. The TNCM also provided additional support and linking, if neces-
sary. Furthermore, the TNCM regularly assessed details received via tele-
monitoring, video consultations, and mobile phone, and bridged
communication between the RTR and the STP. The STP obtained signifi-
cant details and cooperated closely with the resident nephrologists.
In emerging acute care situations, the TNCM triggered the second case
management process. The TNCM provided a precise synopsis of all med-
ically significant details to one of the STP immediately after assessment,
enabling the STP to plan provision of instant interventions precisely tai-
lored to the individual’s needs. If necessary, timely video visits with the
STP were organized. The STP either provided medical instructions, initiat-
ing direct treatment at the UMC Freiburg, or arranged prompt linking
to treatment by another specialist within the collaborative framework
(Figure 1).
Variables and measurements
The study variables included medical outcomes, adherence, quality of life,
and costs. Table 2 summarizes research hypotheses, target outcomes,
and measurements.
Data are reported at 0, 3, 6, and 12 months posttransplant. At each time
point, a resident physician and a UMC Freiburg clinician estimated the
RTR’s adherence to the immunosuppressive regimen and provided collat-
eral reports on an ordinal scale. A trained psychologist assessed self-
reports using the (i) Basel Assessment Adherence to Immunosuppression
Scale (BAASIS), (ii) health-related “Fragebogen Alltagsleben” (ALL),
(iii) disease-specific End-Stage Renal Disease Symptom Checklist-Trans-
plantation Module (ESRD-SCLTM), and (iv) Brief Symptom Inventory 18
(BSI-18). These instruments are all standardized and reliable, and have
been validated for use in RTR populations (26–34). The RTR answered a
closed-ended question about their working time percentage. Finally, the
tacrolimus trough level and transplant function were documented. Medical
staff collected the reports from each treating physician and assessed
them meticulously regarding the “hard” target outcomes.
For cost determination, the division for finance and control of the UMC
Freiburg assigned the patient’s unplanned admission diagnoses to the
German diagnosis-related group (DRG) fixed-price system with an aver-
age length of stay, the lowest patient clinical complexity level, and stan-
dardized base rates valid throughout Baden-W€urttemberg, Germany (19).
Regarding assessment of nonadherence, we adopted the definition of
the “Consensus Conference” on nonadherence to immunosuppressants
(35) as a “deviation from the prescribed medication regimen sufficient to
influence adversely the regimen’s intended effect.” Likewise, we fol-
lowed their recommendations for assessment of nonadherence with a
CAS, each of which consisted of one self-report, two clinician reports,
and one tacrolimus assay (21,35). Nonadherence was determined using
the pre-defined CAS cut-off system of Sch€afer-Keller et al. (21). No data
were included following graft loss. To describe the dynamics of nonad-
herence, we further compiled a CAS percentage grading as an interval
rating scale, and transcoded it to the definition of nonadherence (35).
Table 3 shows the corresponding scheme.
Data analyses
Statistical analyses were performed in cooperation with the Center for
Medical Biometry and Medical Informatics, University of Freiburg. The
Shapiro–Wilk test verified that most parameters were not normally dis-
tributed and therefore ANOVA-type statistics (ATS) by Brunner in F1-LD-F1
design (36) were applied using R statistical software version 3.0.0 ©
(https://www.r-project.org; R Foundation for Statistical Computing, Vienna,
Austria) (37), and package nparLD version 2.1 (Free Software Foundation,
Inc., Boston, MA) (38). ATS is suitable for rank-based, nonparametric,
PATIENT
Community Care: University Medical Center Freiburg:
University Medical Center Freiburg:
TRANSPLANT NURSE
CASE MANAGER
SENIOR TRANSPLANT
PHYSICIANS
ACUTE CARE CLINICS
Collaboration Co
lla
bo
rat
ion
ACUTE CARE CLINICS
SPECIALIST PHYSICIANS
OUTPATIENT CLINICS
SPECIAL DEPARTMENTS
including
INTENSIVE CARE
RESIDENT NEPHROLOGISTS
PATIENT
Intaking
Assessment
Monitoring
Li
nk
in
g
Lin
kin
g Pl
an
nin
g
Pl
an
ni
ng Linking
Planning
Planning
Linking
Planning Linking
Medical
Instructions
Self-management
Support
Figure 1: Collaboration structures and information paths in the case management processes for living-donor renal transplant
recipients.
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repeated-measures analyses and permits the covariance matrix to be sin-
gular. It provides reliable results for small sample sizes and data with out-
liers (36). p-values ≤ 0.05 were deemed statistically significant.
All other tests were performed with IBM SPSS Statistics 22.0 (IBM Corp,
Armonk, NY). The proportion of patients showing nonadherence was
compared between groups using a two-tailed Fisher exact test. For post-
hoc tests, two-tailored Mann–Whitney U-tests, Friedman rank sum tests,
and pairwise Wilcoxon signed-rank tests were applied. Post-hoc test
p-values were adjusted with Holm’s sequential Bonferroni procedure (39).
Effect sizes for post-hoc tests were calculated with Cohen’s r ¼ zﬃﬃﬃﬃ
N
p (40).
We used a 2 9 4 design with treatment (TSCMG, SOCG) and post-
transplant time point in months (0mo = baseline assessment at time
Table 2: Hypotheses, outcomes, and measurement for effect determination of the telemedically supported case management group
(TSCMG) compared to the standard of care group (SOCG)
Research hypotheses Target outcomes Measurement instruments and means
Regarding acute care situations, TSCMG and SOCG are different in terms of:
PRIMARY:
Unplanned inpatient hospitalization Unplanned admission rate Sum of unplanned admissions according to all medical reports
SECONDARY:
Unplanned prolonged inpatient
hospitalization
Length of unplanned stay Sum of unplanned inpatient days according to all medical
reports
Unexpected costs for inpatient care Unplanned inpatient care
costs in Euros (€)
Sum of unplanned inpatient care costs according to the
diagnosis-related groups (DRG) fixed-price system in
Germany
Acute rejection risk Rejection rate Sum of biopsy-proven acute rejections
Treatment for acute rejections Length of time before
rejection therapy initiation
Sum of days between first creatinine level increase before a
biopsy-proven rejection and the start of glucocorticoid
therapy according to the patient charts
Preservation of graft function Estimated glomerular filtration
rate (eGFR)
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equations with serum creatinine level in medical reports
Real-life ambulatory care visits Ambulatory care visit rate Sum of ambulatory care visits (outpatient clinic and resident
physicians) according to all physician reports
Regarding the chronic care situation, TSCMG and SOCG are different in terms of:
Immunosuppressive regimen
adherence
Composite adherence score
(CAS) and CAS percentage
grade
 Self-Report in the Basel Assessment of Adherence to
Immunosuppressive Medications Scale (BAASIS)
 Collateral reports (physicians, nurses)
 Hit of target tacrolimus trough levels
Quality of life Psychological and quality-of-
life-questionnaires’
subscale scores
 Fragebogen Alltagsleben (ALL)
 End-Stage Renal Disease Symptom Checklist-
Transplantation Module (ESRD-SCLTM)
 Brief Symptom Inventory 18 (BSI-18)
Return to employment Working time percentage Closed-ended question about working
time percentage
Table 3: Prespecified adherence percentage grading scheme for tacrolimus trough level, collateral report, and self-report
Percentage
grading
Collateral
report
Tacrolimus trough
level (ng/mL) Self-report
Transcoding to
nonadherence
100% 1 (excellent) (4.5–9.0) Adherence in every
aspect
Fully
adherent
90% 1.5 (9.1–9.2) Adherence in every aspect and lacking
memorization of the regimen doses
Fully adherent
80% 2 (good) (9.3–9.5) Adherence except for timing once Partial adherent
70% 2.5 (9.6–9.7) Adherence except for timing once and lacking
memorization of the regimen doses
Partial adherent
60% 3 (fair) (9.8–10.0) Adherence except for taking once Nonadherent
50% 3.5 (10.1–10.2) Adherence except for taking once and lacking
memorization of the regimen doses
Nonadherent
40% 4 (poor) (10.3–10.5) Self-reported timing non-adherence
more often than once
Nonadherent
30% 4.5 (10.6–10.8) Self-reported drug holidays Nonadherent
20% 5 (very poor) (10.9–11.0) Self-reported independent dose reductions Nonadherent
10% 5.5 <4.5 or >11.0 More than one aspect of nonadherence Nonadherent
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point T1, 3mo = T2, 6mo = T3, 12mo = T4). P-values and correspond-
ing ATS are presented as F (df, ∞), with df as numerator degrees of
freedom (N). For two-tailed post-hoc tests, median, interquartile range
(IQR); test value U (Mann-Whitney U-test) or Z (Wilcoxon rang sum
test), p-value, and Cohen’s measure r as effect size are provided. A
sensitivity power analysis using G*Power 3.1.7 (41) showed that for
the sample size of N = 46, an alpha level of 0.05 and a probability of
0.80, a two-tailed Mann-Whitney U-test would be able to detect effect
sizes larger than Cohen’s d = 0.84 (5), respectively Cohen’s r = 0.38
[r = dﬃﬃﬃﬃﬃﬃﬃﬃﬃ
d2þ 4
p ] (42).
Results
Of 56 eligible participants, 5 did not speak German
and 1 died before allocation. Two patients in each
group did not agree to concealed allocation and
declined participation before allocation. One TSCMG
participant subsequently refused ongoing telemonitoring
and two participants finished the SOCG after graft
loss, although their follow-up visits were completed.
Forty-six valid datasets were available for an intent-to-
treat analysis at the end of the data collection period
(Figure 2), which took place between October 2011
and April 2014.
At baseline assessment, characteristics were comparable
between the two groups (Table 4). A detailed clinical
description is provided elsewhere (22).
Results regarding acute care situations
The TSCMG and SOCG differed in their unplanned inpa-
tient hospitalization rate. There was a significant main
effect for treatment, F (1, ∞) = 7.71, p = 0.006, and a
significant interaction F (1.7, ∞) = 4.41, p = 0.017. Post-
hoc analyses showed that the TSCMG had significantly
fewer unplanned admissions at T3 and T4. At 12 months
Enrollment
Allocation
Baseline assessment
0 months after transplantation
1. Follow-up 3 months
after transplantation
2. Follow-up 6 months
after transplantation
3. Follow-up 12 months
after transplantation
Intention-to-treat
analysis
Random assignment and concealed allocation (n = 46)
Excluded (n = 10)
Not meeting inclusion criteria (n = 5)
Declined to participate (n = 4)
Died before allocation (n = 1)
Allocated to standard of care combined with
telemedically-supported case management (n = 23)
Received allocated intervention (n = 23)
 Didnot receive allocated intervention (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 1)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Lost to follow-up (n = 0)
Analysed (n = 23)
Excluded from analysis (n = 0)
Analysed (n = 23)
Excluded from analysis (n = 0)
Discontinued intervention (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 1)
(Suffered graft loss)
Lost to follow-up (n = 0)
Discontinued intervention (n = 1)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
(Suffered graft loss)
(Refused ongoing telemonitoring)
Allocated to standard of care (n = 23)
Received allocated inetervention (n = 23)
Did not received allocated inetervention 
(n = 0)
Assessed for eligibility (n = 56)
Adult living donor kidney transplant recipients
at Medical Center – University of Freiburg
(October 2011 - April 2013)
♦
♦
♦
♦
♦
♦
♦
♦ ♦
Figure 2: Flow diagram of the recruitment and data collection process in a repeated-measure design.
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posttransplant: TSCMG (median = 0 admissions,
interquartile range [IQR] = 1) versus SOCG (median = 2
admissions, IQR = 2), U = 132.5, p = 0.002, r = 0.44.
Additionally, the TSCMG had fewer unplanned prolonged
inpatient hospitalizations with a significant main effect
for treatment, F (1, ∞) = 6.59, p = 0.01; and a significant
interaction, F (1.7, ∞) = 3.8, p = 0.029. The post-hoc
analyses revealed a shorter length of unplanned stay for
the TSCMG at T3 and T4. At 12 months posttransplant:
TSCMG (median = 0 days, IQR = 6) versus SOCG (me-
dian = 13 days, IQR = 23), U = 141.0, p = 0.005,
r = 0.41.
The rate and length of unplanned hospitalizations at T2
were comparable to T3 and T4 for the TSCMG, while
unplanned hospitalization in the SOCG increased signifi-
cantly at each time point (T). For unplanned admissions,
T2 until T3 and T3 until T4 were both Z = 2.74,
p = 0.004, r = 0.40. For length of unplanned stay, T2
until T3 and T3 until T4 were both Z = 2.81, p = 0.002,
r = 0.41. Figure 3 illustrates the interaction of treatment
and time effects regarding unplanned hospitalizations by
group means.
Fewer admission rates and shorter lengths of unplanned
hospitalization in the TSCMG were observed for almost
every diagnosis (Table 5), which was reflected in inpa-
tient care savings of €3417 per patient.
The SOCG suffered two graft losses (acute humoral
rejection, hemorrhage of a native kidney), the TSCMG
none. Biopsy-proven acute rejection rates (Table 5) were
too low for permit comparative analyses. Differences in
ambulatory care visit rates did not reach statistical signifi-
cance at 12 months posttransplant (TSCMG: median =
43 visits, IQR = 22. SOCG: median = 45 visits, IQR =
28), U = 216.5, p = 0.297. Both groups maintained trans-
plant function: the median difference for the change in
estimated GFR between T1 and T4 was +3.6 mL in
TSCMG versus +0.6 mL in SOCG.
Results regarding the chronic care situation
Nonadherence was observed in 56.5% of the SOCG
compared to 17.4% of TSCMG participants (p = 0.013).
The TSCMG and the SOCG also differed in their median
CAS percentage grading scores, with a significant main
effect for treatment, F (1, ∞) = 23.17, p = <0.001; and a
significant interaction, F (2.6, ∞) = 10.58, p < 0.001.
Post-hoc analyses revealed significant differences at all
time points. The group comparison at 12 months post-
transplant showed the following: TSCMG (median =
Table 4: Study sample characteristics at baseline assessment
Telemedically
supported
case
management
group n = 23
Standard of
care
group
n = 23 P-value
Age (years), median
(range)
46 (18–59) 51 (19–66) 0.231
White, n (%) 23 (100) 23 (100) 1.002
Male, n (%) 14 (61) 11 (48) 0.552
Living with partner,
n (%)
19 (83) 18 (78) 1.002
Employed, n (%) 17 (74) 14 (61) 0.532
Living-related donor,
n (%)
9 (39) 12 (52) 0.572
ABO-incompatible,
n (%)
7 (30) 6 (26) 1.002
Serious posttransplant
complications, n (%)
11 (48) 12 (52) 1.002
Number of drugs to take,
median (range)
9 (6–13) 9 (6–17) 0.381
Daily immunosuppression
intake, median (range)
2 (2) 2 (2) 1.002
1Mann–Whitney U test.
2Fisher’s exact test.
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Figure 3: Treatment and time interaction effects regarding unplanned admission rates and length of unplanned stay (inpa-
tient days) per year.
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100%, IQR = 7) versus SOCG (median = 93%, IQR =
21.5), U = 71.5, p < 0.001, r = 0.62.
Figure 4 presents the changes in CAS percentage grad-
ing over time. The median CAS percentage grading for
the TSCMG was always above 97%, and was 100% at
T4, whereas the SOCG score fluctuated between 85%
and 93%. Full adherence (Table 3) at all points was only
achieved in the TSCMG. Adherence throughout follow-up
was demonstrated by 60.9% of patients in the TSCMG
versus only 8.7% of patients in the SOCG. In all other
participants, adherence showed at least some fluctuation
during the first year posttransplant.
In both groups, psychological distress (BSI-18) decreased
and health-related quality of life (ALL) improved signifi-
cantly over the first year posttransplant. Regarding dis-
ease-specific quality of life (ESRD-SCLTM), the TSCMG
and SOCG differed on two subscales: (i) cardiac and
renal dysfunction, and (ii) side effects of corticosteroids.
Figure 5 illustrates that in the TSCMG group, corticos-
teroid side effects and cardiac and renal dysfunction,
decreased significantly at every time point and progres-
sively approached zero. The scores differed from the
SOCG most significantly at (i) T3 (TSCMG [me-
dian = 0.14, IQR = 0.29] versus SOCG [median = 0.29;
IQR = 0.43], U = 132.5; p = 0.004, r = 0.42) and (ii) T4
(TSCMG [median = 0, IQR = 0.2] versus SOCG [me-
dian = 0.4, IQR = 0.6], U = 133, p = 0.004, r = 0.42).
The TSCMG cohort returned to full employment soon
after discharge, as indicated by their median working
time percentages, which remained stable throughout
year 1 posttransplant. The SOCG differed significantly
between the baseline assessment (median = 50%,
IQR = 100) and month 3 posttransplant (median = 0%,
IQR = 50), Z = 2.694, p = 0.006, r = 0.4, and did not
return to full employment within the first posttransplant
year (Figure 6).
Table 5: Differences in number of unplanned admissions and length of unplanned inpatient care
Reasons for unplanned
admissions
12 months posttransplant
Total of admissions (total of inpatient days)
Differences in length of
unplanned inpatient care
Standard of care group
(n = 23)
Telemedically supported
case management group
(n = 23)
Acute rejection 2 9 (73) 1 9 (17) 1 9 (56)
Postrenal azotemia 10 9 (71) 4 9 (15) 6 9 (56)
Urinary tract infection 10 9 (70) 6 9 (27) 4 9 (43)
Enteral infection 6 9 (40) 1 9 (6) 5 9 (34)
Cytomegalovirus infection 3 9 (37) 1 9 (22) 2 9 (15)
Pulmonary infection 4 9 (23) 0 9 (0) 4 9 (23)
Drug-induced leucopenia 2 9 (25) 1 9 (7) 1 9 (18)
Infection of unclear focus 2 9 (13) 0 9 (0) 2 9 (13)
Abdominal abscess 3 9 (49) 2 9 (39) 1 9 (10)
Cardiac arrhythmias 2 9 (5) 0 9 (0) 2 9 (5)
Kidney hemorrhage 1 9 (5) 0 9 (0) 1 9 (5)
Acute tubular necrosis 1 9 (4) 0 9 (0) 1 9 (4)
Drug-induced renal failures 2 9 (7) 2 9 (5) 0 9 (2)
Ischialgia 0 9 (0) 1 9 (1) 1 9 (1)
Total 48 9 (422) 19 9 (139) 29 9 (283)
Median 2 9 (13) 0 9 (0)
Interquartile range 6 (23) 2 (6)
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Figure 4: Levels of adherence performance, dynamics, and
variability. The lower the median CAS percentage grade, the
poorer the estimated adherence to the immunosuppressive regi-
men. Median values are shown as a band in the box plots.
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Discussion
Combining telemedicine and case management during
the first year posttransplant is a novel strategy. These
results confirm that the combination is effective in opti-
mizing evidence-based aftercare. The approach is inter-
disciplinary and the judicious interplay of all parties
improved medium-term outcomes at the patient level.
The TSCMG and the SOCG differed significantly in out-
comes regarding both acute and chronic care situations.
Of pivotal importance for acute care was interactive
access to an expert team who provided verbal assurance
and physical assistance. The amount of additional contact
time differed between cases, but the needs of all 23
RTR were adequately met within the usual STP job pro-
file combined with an extra 50% of a TSCM staff mem-
ber. Prompt support and targeted actions helped avoid
the development of serious complications, and were
available on evenings and weekends when standard facil-
ities were not easily accessible (Table 1). Most admis-
sion diagnoses resulted in a shorter length of unplanned
stay or prevented acute inpatient care entirely. One
would expect unplanned hospitalization rates to stabilize
after month 3 because of lower rejection risk and less
intensive immunosuppression, but this was observed
only for the TSCMG. The interaction of time and treat-
ment effects with an increasing sequence of group dif-
ferences over time indicates efficiency. Both aftercare
strategies resulted in a low rate of acute rejection and
stable graft function. The inpatient care and costs in the
two groups, however, differed considerably: the 23 RTR
in the SOCG were hospitalized 29 times more often and
spent 283 days longer in inpatient care, with correspond-
ingly greater costs. Differences in ambulatory healthcare
visits between groups did not reach statistical signifi-
cance, suggesting that the effectiveness of telemedically
supported case management was the only meaningful
variable in patient care.
Nonadherence to the immunosuppression regimen was
significantly less prevalent, and less variable, in the
TSCMG group versus the SOCG group, with a large
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Figure 5: Corticosteroid side effects and cardiac and renal dysfunction. aSubscale of the End-Stage Renal Disease-Symptom-
Checklist-Transplantation Module (ESRD-SCLTM).
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effect size (Cohen’s r > 0.60). The TSCMG group experi-
enced benefits in disease-specific quality of life in terms
of lower cardiac and renal dysfunction, and corticosteroid
side effects. Compared to a reference group of 458 Ger-
man RTR in whom the median score for corticosteroid
side effects was 0.4 (31), the SOCG scored the same
while the TSCMG had a score of 0.0 at T4. The effect
size was moderate (Cohen’s r > 0.4). Overall, the SOCG
appears to have had suboptimal adaptation processes, as
indicated by the failure to return to full employment dur-
ing the first year posttransplant while the TSCMG man-
aged both a full and an early return.
Starting early, at posttransplant discharge, is rational
because this is a natural point of realignment for
patients. The study results suggest that within the first
3 months, the SOCG and the TSCMG progressed differ-
ently in terms of self-management and self-care, as well
as in self-responsibility for their disease-specific status, a
modus operandi that was then maintained. A chance for
optimal development appeared to have been missed in
the SOCG group by year 1.
The TSCMG exploited the opportunities afforded by the
program. First, applying various different recognized
chronic care methods contributed to the successful out-
comes. Second, instant, individualized transplant-centered
expert support was consistently available when particular
challenges arose, facilitating ideal, patient-driven learning
situations. The focus shifted to successfully overcoming
barriers and being able to ensure adherence. Third, the
success of this telemedical concept is founded on the per-
sonal attributes of the team. Written feedback from
patients elicited spontaneous comments praising the
experience, competency, steadiness, reliability, security,
comprehensiveness, and the personalized approach. This
may explain why almost every patient was fully engaged
throughout the first year posttransplant, with the designed
intervention being implemented without difficulty. A fur-
ther contribution might be the human element underpin-
ning videoconferencing, and that the touch-screen
terminals were found to be easy to use. Some patients
would have appreciated tablets with software for mobile
telemonitoring and video consultation, but understood that
German data protection laws were a barrier to their use.
The TSCMG achieved improved outcomes during the
intervention, but whether the benefits of telemedically
supported case management are sustained long term
remains unclear, an important limitation of this study.
We therefore plan to evaluate the study sample at
5 years posttransplant. A second limitation is that the
intervention is not proven for different types of RTR.
Therefore, we have started evaluating telemedically sup-
ported case management for combined pancreas–kidney
and for deceased-donor kidney transplant recipients.
Third, the findings cannot necessarily be generalized
because of the small sample size and the fact that this
was a single-center study. In addition, patients and physi-
cians were not blinded. However, all treating physicians
naturally set a priority for the best possible, noncompetitive
outcome for every RTR. To control further selection biases,
we used randomization and concealed allocation. We took
care to use validated, reliable, and standardized means for
measurement (26–34) and data were partly assessed
externally. Because of the absence of a “gold standard”
for assessment on nonadherence, we sought to maximize
the sensitivity and accuracy of the measurement (21,35).
After completing the study, the UMC Freiburg adopted
the approach and provided a part-time (50%) TNCM posi-
tion. A thorough budget impact analysis, the details of
which would exceed the scope of this report, indicated
that the intervention could be implemented in medium-
and high-volume transplant centers. We would anticipate
the results reported here to be replicable in higher
patient numbers if the nurse support time was scaled up
accordingly. The current reimbursement practice may be
the main hurdle for implementation.
This is the first randomized, controlled trial to evaluate
telemedically supported case management. Application
of this approach was associated with medical, disease-
specific, and social advantages at the patient level, as
well as cost savings for health payers. This comparative
effectiveness research has demonstrated the potential of
telemedically supported case management to optimize
routine evidence-based posttransplant aftercare and sup-
port its application at tertiary care hospitals. It provides a
basis for a multicenter randomized trial to verify these
outcomes in the medium and long term.
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